Image

Global Scarlet Fever Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Dec 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Scarlet Fever Market, By Treatment (Antibiotics and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Scarlet Fever Market

Scarlet Fever Market Analysis and Size

The global scarlet fever market is expected to witness significant growth during the forecast period. Growing diagnosis rates and increasing government initiatives boost up market growth. Furthermore, increasing research and development, rise in investment for pharmaceutical industries expansion and growing healthcare expenditure act as market growth opportunities. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global scarlet fever market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Scarlet Fever Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Antibiotics and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Melinta Therapeutics LLC (U.S.), KYORIN Pharmaceutical Co., Ltd (Japan), NIKSAN PHARMACEUTICAL (India), Maya Biotech Private Limited (India)

Market Opportunities

  • Increasing Treatment Approaches
  • Increasing Demand for Retail Pharmacies

Market Definition

Scarlet fever, also known as scarlatina, is caused by the bacteria streptococcus pyrogenes. According to the several studies conducted, bacterial species supported by viral infections induce scarlet fever. The viral infection to bacterial pathogens allows bacterial species to form three types of antigens called superantigens, assisting the bacterial species enter the child’s tissue and escape the white blood cells, the part of the immune system. Numerous symptoms associated with scarlet fever include sore throat, fever, headache, coughing, sneezing, swollen lymph nodes, among others. The severe complications caused by scarlet fever include brain abscess, meningitis, pneumonia, and osteomyelitis.

Global Scarlet Fever Market Dynamics

Drivers

  • Increased Cases of Scarlet Fever

The increasing prevalence of scarlet fever is expected to boost the market growth. As many as 10% of the population contracts group A streptococcal pharyngitis. Among this group, as many as 10% develop scarlet fever. Thus, these rising cases demand higher treatment types, consequently boosting market growth.

  • Growing Demand for Advanced Diagnostic Techniques

Scientists are developing advanced techniques for the betterment of patients. RADT (rapid antigen detection test) was performed to confirm the scarlet fever with pharyngitis and is considered the ultimate standard diagnostic test. All these are expected to boost the market.

Opportunities

  • Increasing Treatment Approaches

The several treatment options are assisting in patient recovery. Antibiotics are the most common treatment option recommended for scarlet fever treatment. Penicillin or amoxicillin is the potential choice of antibiotic for scarlet fever treatment. Though, some patients have been witnessed to allergic to penicillin and thus are recommended with narrow-spectrum cephalosporins (cephalexin, cefadroxil), azithromycin, clarithromycin and clindamycin, among others. This creates more opportunities to the market.

  • Increasing Demand for Retail Pharmacies

The rise in the number of scarlet fever therapeutics being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients choose retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could curb the growth of the global scarlet fever market during a forecast period.

  • High Cost

The huge expenditure associated with the antibiotics and other alternatives hamper the market growth. Antibiotics such as penicillin or amoxicillin are really costing high and impeding the market's growth.

This global scarlet fever market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global scarlet fever market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Scarlet Fever Market Scope

The global scarlet fever market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

Route of Administration

  • Oral
  • Parenteral
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Scarlet Fever Market Regional Analysis/Insights

The global scarlet fever market is analyzed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global scarlet fever market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global scarlet fever market throughout the forecasted period due to the increasing prevalence of scarlet fever and increasing research and development activities.  

Asia-Pacific dominates the market due to rising government initiatives for infection control and the adoption of new technologies infection control.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Scarlet Fever Market Share Analysis

The global scarlet fever market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global scarlet fever market.

Key players operating in the global scarlet fever market include:

  • AstraZeneca (U.K.)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Cipla Inc. (India)
  • Melinta Therapeutics LLC (U.S.)
  • KYORIN Pharmaceutical Co., Ltd (Japan)
  • NIKSAN PHARMACEUTICAL (India)
  •  Maya Biotech Private Limited (India)


SKU-
Why Choose Us


Frequently Asked Questions

Factors such as increased cases of scarlet fever and growing demand for advanced diagnostic techniques are acting as the major drivers for the global scarlet fever market.
AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Melinta Therapeutics LLC (U.S.), KYORIN Pharmaceutical Co., Ltd (Japan), NIKSAN PHARMACEUTICAL (India), Maya Biotech Private Limited (India).
The Scarlet Fever Market report is segmented by Treatment, Route of Administration, End-Users, and Distribution Channel
Asia-Pacific dominates the market due to rising government initiatives for infection control and the adoption of new technologies infection control.